Evidence map›Paper›PMID 41965565›Full record

ArticleBMC nephrology2026

An unusual presentation of strongyloidiasis in a patient on chronic dialysis causing clinical deterioration.

Aboubacar Sidiki Fofana, Magara Samaké, Seydou Sy, Hamma Maiga, Modibo Sadessi, Adama Diallo, Youssouf Singadou Ousmane Djiguiba, Abdoulaye Yalcouyé, Youssouf Kamian, Hamadoun Yattara and 1 more

Abstract readCase Reports
In one paragraph

Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Aboubacar Sidiki FofanaNephrology Unit, Fousseyni Daou Hospital, Kayes, Mali. fofaboubacarsidiki@gmail.com.
Magara SamakéNephrology Unit, Fousseyni Daou Hospital, Kayes, Mali.
Seydou SyNephrology and Hemodialysis Department, Point G University Hospital, Bamako, Mali.
Hamma MaigaNational Institute of Public Health, Bamako, Mali.
Modibo SadessiKayes Biomedical Analysis Laboratory <<LABIOKA>>, Kayes, Mali.
Adama DialloKayes Biomedical Analysis Laboratory <<LABIOKA>>, Kayes, Mali.
Youssouf Singadou Ousmane DjiguibaNational Centre for Scientific and Technological Research, Bamako, Mali.
Abdoulaye YalcouyéFaculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.
Youssouf KamianPulmonology Unit, Fousseyni Daou Hospital, Kayes, Kayes, Mali.
Hamadoun YattaraNephrology and Hemodialysis Department, Point G University Hospital, Bamako, Mali.
Saharé FongoroFaculty of Medicine and Odontostomatology, University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundStrongyloidiasis is a parasitic infection caused by the helminth Strongyloides stercoralis. Strongyloidiasis is endemic in tropical regions, including Mali. Diffuse forms of the disease occur in seriously immunocompromised patients and those undergoing immunosuppressant therapies, such as corticosteroids. We report an unusual case of disseminated strongyloidiasis in a patient undergoing chronic hemodialysis in Mali. CASE PRESENTATION: A 62-year-old woman from Mali with a past medical history of diabetic nephropathy was followed in our clinic. She has been undergoing chronic hemodialysis for two years due to diabetic nephropathy. She denied taking corticosteroids or immunosuppressant medications. Over three months, she presented with symptoms of non-specific abdominal pain, with alternating of diarrhea and constipation, and a dry cough with fever. At admission, physical examination found an altered general condition, blood pressure of 140/90 mmHg, heart rate of 97 beats per minute, and temperature of 38.7 °C. Ancillary tests, including urine culture, identified Strongyloides stercoralis. This was confirmed by parasitological examination of stool samples taken on three successive occasions. The patient was treated with oral 200 µg/kg ivermectin combined with 400 mg albendazole. His clinical presentation got improved significantly. One month later, the repeated parasitological and urinary tests were negative.

conclusionSevere strongyloidiasis is commonly seen in immunocompromised patients and usually have poor prognosis. This case highlights the need for thorough investigation of such infections in chronic immunodeficient individuals, often associated with end-stage renal failure. Therefore, we suggest parasitological monitoring or its prophylactic treatment at regular intervals for patients at high risk of developing disseminated and severe strongyloidiasis.

Indexed as

Clinical DeteriorationDiabetic NephropathiesRenal DialysisStrongyloidiasisAnimalsFemaleHumansImmunocompromised HostIvermectinMiddle AgedStrongyloides stercoralisIvermectinDisseminated strongyloidiasisHemodialysisKayes hospitalMali

Identifiers

PMID41965565
PMCPMC13085713

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.